Meet the 2 Newest Investments in Cystic Fibrosis

Individuals with cystic fibrosis, or CF, have relatively few treatment options available to them. Approved medicines largely focus on reducing inflammation and keeping infections at bay -- treating symptoms of the disease, not the cause. For instance, Pulmozyme from Roche (NASDAQOTH: RHHBY  ) was the first approved treatment for CF. The drug is an enzyme that breaks down mucus in the lungs, which improves breathing and the body's ability to clear such mucus. It fetched $305 million in sales for Roche in the first half of this year, but it is approved for multiple indications worldwide and is hardly the best the industry has to offer. 

Promising new research in the genetics of CF is about to change that. Kalydeco from Vertex Pharmaceuticals (NASDAQ: VRTX  ) is approved to treat patients with a certain mutation, G551D, in the gene encoding the CFTR protein, which controls fluid flow in and out of cells. The drug has greatly improved the lives of cystic fibrosis patients with the mutation -- about 4% of all patients -- and generated sales of $160 million in the first half of 2013. Not very promising, but consider that pipeline candidates currently being evaluated in clinical trials that treat another genetic mutation, F508del, could allow Vertex to treat 90% of the cystic fibrosis population and generate peak sales of $1.7 billion by 2018.  

The prospects have spurred others to dig into genetic data to unveil targets for treating cystic fibrosis more effectively. Who are the latest entrants? Are they investment-worthy on the backs of CF treatments alone? Fool contributor Maxx Chatsko explains in the following video.

Biotech innovation doesn't end with cystic fibrosis
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2659874, ~/Articles/ArticleHandler.aspx, 9/29/2016 4:52:28 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,143.45 -195.79 -1.07%
S&P 500 2,151.13 -20.24 -0.93%
NASD 5,269.15 -49.39 -0.93%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/29/2016 4:01 PM
ABBV $62.82 Down -1.40 -2.18%
AbbVie CAPS Rating: ****
PTCT $11.56 Down -0.17 -1.45%
PTC Therapeutics CAPS Rating: **
VRTX $85.00 Down -3.84 -4.32%
Vertex Pharmaceuti… CAPS Rating: ****
RHHBY $31.01 Down -0.56 -1.77%
Roche Holding Ltd.… CAPS Rating: *****